Methods and compositions for attenuated chlamydia as vaccine and vector
View Patent ↗The present invention provides Chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.
1. An isolated Chlamydia trachomatis cell comprising:
a) a substitution at Q117 in open reading frame CT849, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:1; and
b) a G216* mutation in open reading frame CT389, wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:2,
wherein said Chlamydia trachomatis cell has a phenotype due to said substitution of (a) and said mutation of (b) of attenuated pathogenicity.
2. The isolated Chlamydia trachomatis cell of claim 1 , wherein the substitution in open reading frame CT849 is Q117E.
3. The isolated Chlamydia trachomatis cell of claim 1 , further comprising a substitution at G322 in open reading frame CT389.
4. The isolated Chlamydia trachomatis cell of claim 1 , further comprising a mutation in the open reading frame CT135 selected from the group consisting of:
a) a CT135fs29 mutation;
b) a CT135E88* mutation;
c) a CT135fs145 mutation; and
d) any combination of (a) (c) above,
wherein said amino acid numbering is based on the amino acid sequence of SEQ ID NO:3.
5. The isolated Chlamydia trachomatis cell of claim 1 , further comprising a heterologous nucleic acid molecule.
6. A composition comprising the isolated Chlamydia trachomatis cell of claim 1 and a pharmaceutically acceptable carrier.
7. A composition comprising the isolated Chlamydia trachomatis cell of claim 5 and a pharmaceutically acceptable carrier.
8. The isolated Chlamydia trachomatis cell of claim 3 , wherein the substitution at G322 in open reading frame CT389 is G322R.